Kura Oncology, Inc. (KURA) Stock Grade

About Kura Oncology, Inc.'s fundamentals

Kura Oncology is a biotechnology company with a market capitalization of $911.0 million that is actively growing its revenue at a rate of 25.2% year-over-year. However, the company is currently unprofitable, reporting a net loss in its latest annual statement with a net margin of -413.0%, meaning it is spending substantially more than it generates in revenue. The company does not pay a dividend, which is typical for early-stage biotech firms focused on research and development. Standard profitability metrics like P/E ratio and return on equity are not applicable due to the company's loss-making status.